ICLRNasdaqServices-Commercial Physical & Biological Research
ICON PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 27, 2026
$168.14−2.04 (-1.20%)
Close on Oct 19, 2026
- Market cap
- $13.01B
- P/E (TTM)
- 300.2
- Dividend yield
- –
ICON PLC revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ireland | $3.18B | $2.70B | $2.32B | $1.98B | $1.37B | $1.18B | $1.25B | $1.07B | $424.29M | $410.57M | 38.6% | +17.7% |
| United States | $2.52B | $2.98B | $3.28B | $3.57B | $2.58B | $925.56M | $892.50M | $894.98M | $791.54M | $763.82M | 30.6% | -15.4% |
| Rest of Europe | $1.59B | $1.56B | $1.57B | $1.62B | $1.18B | $416.88M | $388.92M | $379.88M | $337.11M | $313.19M | 19.3% | +2.0% |
| Rest of World | $951.90M | $942.64M | $884.50M | – | – | – | – | – | – | – | 11.5% | +1.0% |
| Other | – | $942.64M | $884.50M | $563.86M | $358.40M | $273.55M | $271.59M | $254.72M | $205.50M | $178.91M | – | – |
From the segment and revenue-disaggregation notes of ICON's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.